An 80-year-old lady in good health with primary angle closure glaucoma (OU) since 15 years and on topical levobunalol 0.5%, bimatoprost 0.03%, and dorzolomide 2% had her intraocular pressure (IOP) under control. During her visit in January 2019, her visual fields showed progression and IOP recorded was 20 and 26 mmHg in OD and OS, respectively. Bimatoprost 0.03% was stopped and changed to brimonidine 0.2%. Two weeks after the use of brimonidine, she presented with raised IOP (26 mmHg) in both eyes with granulomatous anterior uveitis [ Fig. 1a and b] , with no posterior segment involvement.
What is Your Next Step?
A. Investigate for systemic causes of granulomatous uveitis B. Start on topical steroids C. Start on systemic steroids or immunosuppressants if the inflammation is not under control D. Stop brimonidine.
Correct Answer: D Findings
The patient was asked to stop brimonidine eye drops and was started on prednisolone acetonide 1% eye drops. Investigations to rule out systemic causes of granulomatous uveitis like Mantoux test, chest X-ray, serum angiotensin converting enzyme, and venereal disease research laboratory test were not contributory. One week later, she had no signs of ocular inflammation. She had a similar history in the past on changing the antiglaucoma medication. At 3 months of follow-up after stopping the drug, there were no signs of inflammation in both eyes.
Diagnosis
Brimonidine-induced granulomatous uveitis
Discussion
Allergic conjunctivitis and skin excoriation are the most common side effects of brimonidine. [1] Although rare, brimonidine can cause granulomatous uveitis in the elderly. [2, 3] It usually occurs 7-12 months after starting the drug and is seen in elderly patients. The uveitis usually resolves with drug discontinuation. In our case, the uveitis occurred 2 weeks after starting the drug. It has been hypothesized that brimonidine induces T-cell/macrophage activation and interaction.
[3] Thus, though rare, granulomatous uveitis can occur with brimonidine and clinicians need to be aware of its usage in elderly.
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